News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Robeco Sells Entire Stake In Johnson & Johnson Target Crucell N.V.
October 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AMSTERDAM, Oct 15 (Reuters) - A shareholder in Dutch biotech Crucell (CRCL.AS), subject to an agreed offer by U.S.-based Johnson & Johnson (JNJ.N), has sold all its shares in the firm, underlining market doubts a higher offer will emerge.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
Johnson & Johnson Family of Companies
MORE ON THIS TOPIC
Mergers & acquisitions
Gilead Doubles Down on CAR T With $7.8B Arcellx Acquisition
February 23, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Novartis Bets Up to $1.7B in Cardio-Focused Peptide Partnership
February 19, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline
February 18, 2026
·
2 min read
·
Tristan Manalac
Venture capital
Early-Stage Biotechs Suffer in 2025 As VC Shuns Risk: PitchBook
February 18, 2026
·
2 min read
·
Annalee Armstrong